#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Rectal cancer Duchenne muscular dystrophy gene carrier Dedifferentiated liposarcoma Small intestine leiomyosarcoma B precursor type acute leukaemia Mycobacterium abscessus infection Ovarian cancer stage III Arteriovenous malformation Keratosis follicular X-linked lymphoproliferative syndrome Liposarcoma Polymyositis Hypochromic anaemia SAPHO syndrome PIK3CA related overgrowth spectrum More trials…

    Learn about Rare Diseases

    Glycogen storage disease type II – Treatment Cerebral arteriovenous malformation haemorrhagic – Trials in Disease Richter’s syndrome – Life with Disease Hereditary optic atrophy – Treatment Glomerulonephritis membranoproliferative – Trials in Disease Hereditary ataxia – Treatment Acute respiratory distress syndrome – Treatment Immunodeficiency congenital – Basic Information Cytokine release syndrome – Treatment Skin angiosarcoma – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Noradrenaline Tartrate Abbv-668 Golexanolone Tobramycin BIIB115 Vo659 Mk-1167 Tucidinostat Rilpivirine Hydrochloride Dosulepin Hydrochloride GOLD SODIUM THIOSULFATE Tinengotinib 12 Grass Pollen Mixture Gilteritinib Fulvestrant Pitavastatin Calcium Ixekizumab Hydroxyzine Hydrochloride TUB-030 Golcadomide More therapies…

    Learn about Your Condition

    Viral infection Cancer pain Kearns-Sayre syndrome Retinoblastoma Asplenia Ocular hypertension Urea cycle disorder Deafness neurosensory Malformation venous Colonoscopy Ischaemic skin ulcer Normal pressure hydrocephalus Cardiogenic shock Factor IX deficiency Stress More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Squamous cell carcinoma of skin

  • A study of onfekafusp alfa and bifikafusp alfa injected into tumors for patients with advanced skin squamous cell cancer who did not respond to or could not tolerate previous treatment

    Recruiting

    2 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of skin
    Investigated Drugs:
    • Bifikafusp Alfa
    • Onfekafusp Alfa
    Austria Germany Greece Italy The Netherlands Spain

  • Study of nivolumab and ipilimumab combination therapy as an alternative to surgery and radiation in patients with skin squamous cell carcinoma

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Ipilimumab
    • Nivolumab
    The Netherlands

  • Study on Cemiplimab for Patients with High-Risk Stage III/IV Cutaneous Squamous Cell Carcinoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of skin
    Investigated Drugs:
    • Cemiplimab
    Italy

  • Study of Nivolumab and Nivolumab Plus Relatlimab for Patients with Advanced or Metastatic Skin Squamous Cell Carcinoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of skin
    Investigated Drugs:
    • Relatlimab
    • Nivolumab
    Austria

  • Phase II Study of Cemiplimab to Spare Surgery in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of skin
    Investigated Drugs:
    • Cemiplimab
    Italy

  • A study of cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of skin
    Investigated Drugs:
    • Cemiplimab
    Spain
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!